An anonymous director reports

LEADING INDEPENDENT PROXY ADVISOR GLASS LEWIS RECOMMENDS SHAREHOLDERS VOTE THE GREEN PROXY FOR ALL MEDIPHARM DIRECTOR NOMINEES

Leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC published a report on June 12, 2025, recommending that Medipharm Labs Corp. shareholders vote the green proxy or voting instruction form for the company's nominees for the board of directors at the upcoming annual and special meeting of shareholders on June 16, 2025.

Glass Lewis is the second independent proxy advisory firm to recommend voting for the company's nominees for the board, following a similar recommendation issued by Institutional Shareholder Services (ISS) on May 30, 2025.

Vote for the highly qualified Medipharm nominees

Medipharm urges shareholders to vote only using the green proxy or green voting instruction form in support of all of the company's nominees and resolutions. All votes must be received no later than 3 p.m. Eastern Time on Friday, June 13, 2025.

To ensure your vote is counted, shareholders are encouraged to pro-actively contact their broker to obtain their 16-digit control number associated with the green management proxy. Once received, you can cast your vote by visiting the Medipharm AGM website.

You may receive materials or outreach from the dissident -- please disregard any such communications and vote only using the green proxy in support of the company's nominees.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a good manufacturing practices-certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing practices licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the United States Food and Drug Administration.

In 2023, Medipharm acquired VIVO Cannabis Inc., which expanded Medipharm's reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Australia Pty. Ltd. and Beacon Medical Germany GmbH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

The company carries out its operations in compliance with all applicable laws in the countries in which it operates.

Shareholder voting assistance

If you have any questions or require any assistance in executing your green proxy or voting instruction form, please call Sodali & Co. at:

North American toll-free number:   1-888-777-2059

Outside North America, banks, brokers and collect calls:  1-289-695-3075

E-mail:  assistance@investor.sodali.com

North American toll-free facsimile:  1-877-218-5372

We seek Safe Harbor.